Cannabis is popularly believed to be a relatively benign substance. Cannabis is also considered to have potential medical benefits, and medical marijuana has been legislated in many parts of the world. However, a recent meta-analysis found that cannabinoids were associated with only modest benefits for chemotherapy-related nausea and vomiting, small and inconsistent benefits for pain and spasticity, and inconclusive benefits for other indications such as improvement of appetite and weight, reduction in tic severity, and improvement of mood or sleep. On the flip side, cannabinoids and cannabis have acute and long-term adverse effects. In randomized controlled trials, cannabinoids increase the risk of total adverse events, serious adverse events, and dropout due to adverse events. Cannabis impairs cognition, and driving after cannabis use is associated with an increased risk of traffic accidents, including fatal accidents.

In Table 1. In summary, all comparisons were against placebo, and cannabis use may benefit patients such as those who suffer from chronic pain or spasticity. Other benefits, such as for improving appetite and weight related nausea and vomiting (28 studies; pooled n = 2,454), or spasticity (14 studies; pooled n = 2,280). Most of these studies evaluated nabiximols (19 studies), nabilone (20 studies), or dronabinol (13 studies); only 2 studies evaluated cannabis. Most of the studies were placebo-controlled; the rest employed a variety of active controls. Only 34 trials were parallel-group studies; the rest were crossover studies. Only 4 RCTs were considered to be at low risk of bias; principal sources of bias related to incomplete outcome data, especially with regard to study withdrawals. The pooled sample included 6,462 patients. Because studies were widely heterogenous in clinical characteristics, only some were appropriate for the efficacy analyses; the rest contributed to the adverse effects analyses.

Important efficacy outcomes from the meta-analysis are presented in Table 1. In summary, all comparisons were against placebo, and cannabinoids were not a magic bullet for any indication. Cannabinoids were associated with modest benefits for chemotherapy-related nausea and vomiting, but only small and inconsistent benefits for pain and spasticity. Other benefits, such as for improving appetite and weight in specified conditions, reducing tic severity, and facilitating sleep seemed possible, but the data were not sufficient in terms of quality or consistency for firm conclusions to be drawn.3

Cannabis and Global Burden of Disease

Data from the Global Burden of Disease Study 2010 suggested that, during 2010, an estimated 13.1 million persons were dependent on cannabis; the point prevalence was 0.19%. The prevalence was higher in high-income regions, peaked in the 20- to 24-year age band, and
was nearly twice as high in males as in females. Cannabis dependence was associated with 2,057,000 years of life lived with disability and the same number of disability-adjusted life-years. In Canada, these statistics were estimated to be 10,533 years of life lost due to premature mortality, 55,813 years of life lost due to disability, 66,346 disability-adjusted life-years, and 287 deaths in 2012.

Cannabis use is associated with short- and long-term adverse consequences. These are discussed in subsequent sections.

### Short-Term Risks Associated With Cannabis and Cannabinoid Use

**Adverse effects of cannabinoids.** In the meta-analysis that they described, Whiting et al also examined adverse outcomes associated with cannabinoid treatments. These are presented in Table 2. In summary, the RCT data showed that cannabinoids were associated with a significant adverse effect burden, including the risk of serious adverse events. There were many specific adverse events the risks of which were significantly increased; confidence intervals were mostly narrow, indicating high precision of estimates, and heterogeneity across RCTs was mostly low to moderate, indicating that the findings were similar across studies.

**Cannabis use and impaired cognition.** Cannabis use has long been suggested to adversely affect cognition. A systematic review concluded that verbal learning and memory and attention are functions that are most consistently impaired by acute and chronic cannabis use. Psychomotor impairment occurs most obviously during acute intoxication but may be detected in chronic users, as well. The neuropsychological deficits probably arise from impairments that have been identified in hippocampal, prefrontal, subcortical, and other brain networks that subserve cognition.

**Cannabis use and the risk of motor vehicle accidents.**

A systematic review and meta-analysis of 9 studies (pooled N = 49,411) showed that driving after cannabis use was associated with a doubled risk of motor vehicle accidents.

<table>
<thead>
<tr>
<th>Table 1. Medical Benefits of Cannabinoids in RCTs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cannabinoids were superior to placebo for relief from chemotherapy-related nausea and vomiting (3 RCTs; 102 patients; response rate, 47% vs 20%; OR = 3.82; 95% CI, 1.55–9.42). However, the quality of the evidence was deemed to be low.</td>
</tr>
<tr>
<td>2. Cannabinoids were superior to placebo for reduction in pain, but the advantage narrowly missed statistical significance (8 RCTs; 1,370 patients; response rate, 37% vs 31%; OR = 1.41; 95% CI, 0.99–2.00). However, the advantage for cannabinoids on a 0–10 point pain assessment scale was significant, though small (6 RCTs; 948 patients; WMD = −0.46; 95% CI, −0.80 to −0.11). Benefits were also observed on other but not all pain outcome measures. The quality of the evidence was deemed to be mostly moderate.</td>
</tr>
<tr>
<td>3. In most analyses, cannabinoids failed to outperform placebo for the reduction of spasticity in patients with multiple sclerosis or paraplegia. The quality of the evidence was deemed to be low to moderate.</td>
</tr>
<tr>
<td>4. Cannabinoids increased weight in patients with HIV/AIDS (4 studies; pooled N = 255), improved sleep in patients with sleep disorders (2 studies; pooled N = 54) and other disorders, and reduced the severity of tics in Tourette’s disorder (2 studies; pooled N = 36). However, the benefits were mostly inconsistent, and the quality of the evidence was deemed to be low.</td>
</tr>
<tr>
<td>5. What little evidence was available did not encourage the use of cannabinoids for anxiety or depression.</td>
</tr>
<tr>
<td>6. Heterogeneity was low in most of the analyses.</td>
</tr>
</tbody>
</table>

*Based on meta-analysis by Whiting et al. Abbreviations: CI = confidence interval, HIV/AIDS = human immunodeficiency virus/acquired immune deficiency syndrome, OR = odds ratio, RCT = randomized controlled trial, WMD = weighted mean difference.

<table>
<thead>
<tr>
<th>Table 2. Adverse Events Associated With Cannabinoids in RCTs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cannabinoids were associated with more AEs (29 studies; 3,714 patients; OR = 3.03; 95% CI, 2.42–3.80), more serious AEs (34 studies; 3,248 patients; OR = 1.41; 95% CI, 1.04–1.92), and more dropout due to AEs (23 studies; 2,755 patients; OR = 2.94; 95% CI, 2.18–3.96) than placebo or comparator treatments.</td>
</tr>
<tr>
<td>2. Almost all the cannabinoids were associated with a significantly greater risk of AEs than placebo. The exception was dronabinol; whereas the odds of an AE were trebled with dronabinol, the risk narrowly escaped statistical significance.</td>
</tr>
<tr>
<td>3. Individual AEs significantly more common with cannabinoids included dizziness (41 studies; OR = 5.09), dry mouth (36 studies; OR = 3.40), nausea (30 studies; OR = 2.08), fatigue (20 studies; OR = 2.00), somnolence (26 studies; OR = 2.83), euphoria (27 studies; OR = 4.08), vomiting (17 studies; OR = 1.67), diarrhea (17 studies; OR = 1.65), disorientation (12 studies; OR = 5.41), asthenia (15 studies; OR = 2.03), drowsiness (18 RCTs; OR = 3.68), confusion (13 studies; OR = 4.03), problems with balance (6 studies; OR = 2.62), and hallucinations (10 studies; OR = 2.19). The CIs were mostly narrow, and heterogeneity was mostly low to moderate.</td>
</tr>
</tbody>
</table>

*Based on meta-analysis by Whiting et al. Abbreviations: AE = adverse event, CI = confidence interval, OR = odds ratio, RCT = randomized controlled trial.
driving simulation studies have consistently shown that cannabis dose-dependently impairs psychomotor skills; this lends support to the hypothesis that cannabis use is a specific risk factor for traffic accidents.

Long-Term Risks Associated With Cannabis Use

**Dependence.** About 1 in 10 users of cannabis may develop dependence characterized by the occurrence of a withdrawal syndrome after abstinence. This withdrawal syndrome peaks 2-3 days after quitting and is mostly complete by 1 week; however, sleep disturbances and vivid dreams may persist for 2-3 weeks. Cannabis may also be a gateway drug that increases the risk of more serious forms of drug abuse and dependence.8

**Impaired cognition.** Impairments continue to be demonstrable in several cognitive domains even after discontinuation of cannabis use.7,12 Such impairments may represent reverse causality; that is, persons who have poorer cognitive functioning may be more vulnerable to cannabis use and abuse. Such impairments may also represent residual cannabis effects, or the effects of cannabis withdrawal. In this context, a meta-analysis of 13 studies that examined cognition after > 25 days of abstinence found no impairment in any of 8 assessed domains, or in global neurocognitive performance.12

Cannabis use in childhood and adolescence has been associated with neuropsychological decline (that persists even after cannabis discontinuation) and lower IQ.13,14; however, this finding may be related to confounding rather than to the cannabis use.14,15

The adverse impact on cognition could conceivably compromise social adjustment and vocational success.

**Respiratory disease.** Cannabis users inhale more smoke and inhale more deeply than tobacco users, and have a 5-fold increase in carboxyhemoglobin concentration. Smoking 1 cannabis cigarette is associated with the airflow obstruction resulting from smoking 2.5–5.0 cigarettes. Cannabis smoking is associated with respiratory risks similar to those associated with cigarette smoking.11,17

**Cancer.** Most carcinogens present in tobacco are also present in cannabis.11 This may explain why cannabis use is associated with an increased risk of neoplastic diseases such as oropharyngeal cancers,11 lung cancer,17 and testicular cancer.18 The evidence, however, is weak and inconsistent; but this should not be considered reassuring; rather, it reflects the paucity of research on the subject.

**Cannabis and pregnancy.** Constituents of cannabis cross the placental barrier, are found in breast milk, and can therefore affect pregnancy outcomes and neurodevelopment. Adverse outcomes associated with cannabis exposure during pregnancy include fetal growth restriction, preterm birth, and stillbirth. The findings are inconsistent and hard to interpret because of confounding related to tobacco use and marijuana potency.21

Brown et al22 described a small cross-sectional survey in which pregnancy outcomes were examined in 344 young (mean age = 25.5 years) aborigine women who were studied using a questionnaire that was administered 4–12 (mean = 6.7) months after delivery. Cannabis use during pregnancy was recorded in 20.5% of the women, and smoking in 52%. Relative to infants exposed to neither cannabis nor tobacco during pregnancy, and after adjusting for education, stressful events/social health issues, and other potential confounds, infants exposed to cannabis were observed to be at higher risk of low birth weight (OR = 3.9; 95% CI, 1.4–11.2); birth weight was lower by 419 (95% CI, 165–672) g. The increased risk of smallness for gestational age (OR = 3.8; 95% CI, 1.9–7.6) was no longer significant in an adjusted analysis, and there was no increased risk of preterm birth in any analysis. This study was very small, ascertainment of risk factors was retrospective, dose-dependent and trimester-specific risks could not be examined, the use of alcohol was not adjusted for, only a few pregnancy outcomes were studied, and, of course, causality cannot be attributed in studies with this design. However, the findings are reasonably consistent with those of earlier studies.21

**Other risks.** Cannabis use may be associated with xerostomia and oral health problems, impaired female fertility, and many other long-term risks.11 Early cannabis use may compromise the developing brain, adversely affect educational attainment, and have long-term adverse effects on social and occupational success.8 There is a strong association between cannabis use and psychosis, and this will be discussed in a later article in this column.

**General Notes**

Cannabinoids can be administered by several routes: orally (swallowed), sublingually, or topically. Cannabinoids can be taken as an herb (of variable potency), extracted naturally from the plant, isomerized from cannabidiol, or synthesized. Cannabis can be smoked, inhaled, mixed with food, made into sweets, or made into tea. The bioavailable substances and their quantities therefore vary widely, depending on form and route of use, making it hard to interpret study results and generalize to other forms and routes of use of the substance.

The use of medical marijuana is a particular problem. This is because the contained ingredients are many, running into hundreds, and issues related to pharmacology and drug interactions are poorly understood; the potency and balance of the contained active ingredients vary, making precise dosing impossible; and use is hard to control, leading to risks of intoxication, accidents, dependence, psychosis, and other adverse outcomes. These and other concerns related to medical marijuana have been well discussed elsewhere.16,23

In summary, there needs to be a substantial body of research (similar to that for approved medications) on the...
safety and efficacy of specific forms and doses of cannabinoids before recommendations can be made; until then, all that can be stated is that cannabinoids are inconsistently effective in various medical situations, that cannabis and cannabinoids carry short- and long-term risks, and that the risk-benefit profile of cannabinoids for different indications is incomplete. Given the high adverse effect burden associated with cannabinoids, placebo-controlled research needs to be conducted in treatment-resistant populations; studies in nonrefractory populations should include active treatment arms to compare risk-benefit ratios; long-term data on safety and efficacy are necessary; and safety and efficacy in special populations require to be determined.

Parting Notes

Those who consider cannabis benign and support medical use of marijuana need to keep at least 2 additional points in mind. One is that beliefs about the safety of marijuana may be based on (old) research that was conducted on subjects who were using milder forms of the substance; today, street versions of cannabis are far more potent in psychotogenic content than earlier, and the reassuring findings of some previous studies may no longer be valid. The other is that scientific drug development is a rigorous process, and regulatory bodies have stringent requirements to be fulfilled before drugs are approved for marketing. These safeguards are necessary to protect patients and the public at large. The existent safety and efficacy data for medical marijuana fall well short of these standards.

REFERENCES